Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (32)

2021

  1. Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain

    Clinical Infectious Diseases

  2. Trade-offs between individual and ensemble forecasts of an emerging infectious disease

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity

    International Journal of Infectious Diseases, Vol. 97, pp. 290-292

2018

  1. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain

    European Journal of Gastroenterology and Hepatology, Vol. 30, Núm. 9, pp. 1060-1062

2017

  1. Hepatitis delta and HIV infection

    AIDS, Vol. 31, Núm. 7, pp. 875-884

2016

  1. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection

    Liver International, Vol. 36, Núm. 9, pp. 1258-1266

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  3. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1

  4. Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfected patients on Hepatitis C Virus therapy

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 3, pp. 226-231

2015

  1. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients

    Journal of Clinical Virology, Vol. 65, pp. 62-67

2014

  1. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 2, pp. 113-119

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2011

  1. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype

    HIV Medicine, Vol. 12, Núm. 8, pp. 487-493

  2. The expansion ability but not the quality of HIV-specific CD8 + T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors

    Immunology, Vol. 134, Núm. 3, pp. 305-313

2009

  1. MDE for device driver development

    Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)

2004

  1. Benefits in the lipid profile after substitution of abacavir for stavudine: A 48-week prospective study

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 12, pp. 1289-1292

  2. Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study

    Clinical Infectious Diseases, Vol. 38, Núm. 1, pp. 128-133

2003

  1. First-line therapy and mitochondrial damage: Different nucleosides, different findings

    HIV Clinical Trials, Vol. 4, Núm. 1, pp. 11-19

  2. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy

    AIDS, Vol. 17, Núm. 6, pp. 921-924

2001

  1. Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients

    Intervirology, Vol. 44, Núm. 6, pp. 339-343